Tianda Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Tianda Pharmaceuticals's earnings have been declining at an average annual rate of -41.5%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been declining at an average rate of 0.8% per year.
Belangrijke informatie
-41.5%
Groei van de winst
-41.5%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 5.6% |
| Inkomstengroei | -0.8% |
| Rendement op eigen vermogen | -8.7% |
| Nettomarge | -12.3% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Lacklustre Performance Is Driving Tianda Pharmaceuticals Limited's (HKG:455) 25% Price Drop
Oct 28
Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected
Aug 16Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?
Jun 20There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump
Mar 27Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)
Mar 02Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?
May 23Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?
Dec 06Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?
Jan 11Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?
Aug 05Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?
Dec 11Opbrengsten en kosten
Hoe Tianda Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 385 | -47 | 213 | 12 |
| 31 Mar 24 | 458 | -36 | 242 | 12 |
| 31 Dec 23 | 532 | -24 | 271 | 13 |
| 31 Dec 22 | 547 | -55 | 286 | 36 |
| 30 Sep 22 | 523 | -18 | 276 | 25 |
| 30 Jun 22 | 517 | -19 | 273 | 20 |
| 31 Mar 22 | 510 | -20 | 269 | 16 |
| 31 Dec 21 | 517 | -25 | 270 | 12 |
| 30 Sep 21 | 523 | -30 | 270 | 8 |
| 30 Jun 21 | 499 | -28 | 276 | 10 |
| 31 Mar 21 | 474 | -27 | 282 | 12 |
| 31 Dec 20 | 445 | -21 | 285 | 10 |
| 30 Sep 20 | 417 | -15 | 289 | 8 |
| 30 Jun 20 | 454 | -6 | 320 | 5 |
| 31 Mar 20 | 491 | 3 | 350 | 2 |
| 31 Dec 19 | 507 | 3 | 374 | 4 |
| 30 Sep 19 | 523 | 3 | 398 | 7 |
| 30 Jun 19 | 525 | 3 | 403 | 7 |
| 31 Mar 19 | 527 | 3 | 408 | 7 |
| 31 Dec 18 | 514 | 6 | 397 | 5 |
| 30 Sep 18 | 501 | 10 | 386 | 3 |
| 30 Jun 18 | 431 | 10 | 319 | 3 |
| 31 Mar 18 | 362 | 10 | 252 | 3 |
| 31 Dec 17 | 295 | 7 | 189 | 3 |
| 30 Sep 17 | 228 | 4 | 125 | 3 |
| 30 Jun 17 | 212 | 8 | 112 | 3 |
| 31 Mar 17 | 196 | 12 | 100 | 3 |
| 31 Dec 16 | 190 | 14 | 99 | 2 |
| 30 Sep 16 | 184 | 15 | 99 | 0 |
| 30 Jun 16 | 188 | 11 | 100 | 1 |
| 31 Mar 16 | 193 | 7 | 101 | 1 |
| 31 Dec 15 | 184 | 0 | 102 | 1 |
| 30 Sep 15 | 175 | -6 | 103 | 2 |
| 30 Jun 15 | 157 | -12 | 103 | 2 |
| 31 Mar 15 | 139 | -18 | 103 | 2 |
| 31 Dec 14 | 164 | -10 | 106 | 2 |
| 30 Sep 14 | 189 | -3 | 108 | 2 |
| 30 Jun 14 | 218 | 10 | 104 | 2 |
| 31 Mar 14 | 247 | 22 | 99 | 2 |
| 31 Dec 13 | 242 | 26 | 94 | 2 |
Kwaliteitswinsten: 455 is currently unprofitable.
Groeiende winstmarge: 455 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 455 is unprofitable, and losses have increased over the past 5 years at a rate of 41.5% per year.
Versnelling van de groei: Unable to compare 455's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 455 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.4%).
Rendement op eigen vermogen
Hoge ROE: 455 has a negative Return on Equity (-8.69%), as it is currently unprofitable.